Search results for "type 2 diabete"

showing 10 items of 662 documents

HEPATITIS C AND DIABETES: THE INEVITABLE COINCIDENCE?

2009

Type 2 diabetes (T2D) and HCV infection are common conditions involving, respectively, at least 170 and 130 million people worldwide. However, the distribution of such cases does not overlap in the same age groups in different geographic areas. Following pioneering reports of increased prevalence of T2D in HCV-positive cirrhosis, interest concerning the relationship between HCV and T2D has escalated. HCV is able to induce insulin resistance (IR) directly and the role of specific viral genotypes responsible for such effect is disputed. IR has consistently been found to be closely linked to fibrosis in HCV infection, although also typically associated with T2D in prefibrotic stages. HCV infec…

Liver CirrhosisMicrobiology (medical)medicine.medical_specialtyCirrhosisHepatitis C virusPopulationHepacivirusType 2 diabetesGlobal Healthmedicine.disease_causeMicrobiologyGastroenterologyRisk FactorsVirologyInternal medicineDiabetes mellitusPrevalencemedicineHumanseducationfatty livereducation.field_of_studydiabetesbusiness.industryHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis C; diabetes; fatty liverHepatitis Cdigestive system diseasesDIABETES HEPATITIS C INSULIN RESISTANCEInfectious DiseasesDiabetes Mellitus Type 2Hepatocellular carcinomaImmunologyInsulin ResistancebusinessViral hepatitis
researchProduct

Magnesium and health outcomes: An umbrella review of systematic reviews and meta-analyses of observational and intervention studies

2020

Purpose: To map and grade all health outcomes associated with magnesium (Mg) intake and supplementation using an umbrella review. Methods: Umbrella review of systematic reviews with meta-analyses of observational studies and randomized controlled trials (RCTs) using placebo/no intervention as control group. We assessed meta-analyses of observational studies based on random-effect summary effect sizes and their p values, 95% prediction intervals, heterogeneity, small-study effects and excess significance. For meta-analyses of RCTs, outcomes with a random-effect p value < 0.005 and a high-GRADE assessment were classified as strong evidence. Results: From 2048 abstracts, 16 meta-analyses an…

0301 basic medicinemedicine.medical_specialtyUmbrella review.Settore MED/09 - Medicina InternaHealth StatusMedicine (miscellaneous)030209 endocrinology & metabolismType 2 diabetesPlaceboDiabetelaw.inventionMagnesium Meta-analysis Pregnancy Diabetes Stroke Umbrella reviewUmbrella review03 medical and health sciences0302 clinical medicineRandomized controlled triallawPregnancyInternal medicinemedicineHumansMeta-analysiMagnesiumStroke030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryDiabetesmedicine.diseaseStrokeMeta-analysisObservational Studies as TopicSystematic reviewMigraineMeta-analysisDietary SupplementsObservational studybusiness
researchProduct

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure

2020

AIMS: Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and is related with worse outcomes. Insulin treatment is associated with sodium and water retention, weight gain, and hypoglycaemia-all pathophysiological mechanisms related to HF decompensation. This study aimed to evaluate the association between insulin treatment and the risk of 1year readmission for HF in patients discharged for acute HF.; METHODS AND RESULTS: We prospectively included 2895 consecutive patients discharged after an episode of acute HF in a single tertiary hospital. Multivariable Cox regression, adapted for competing events, was used to assess the association between insulin treatment and …

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusOriginal Research ArticlesType 2 diabetes mellitusmedicineDiseases of the circulatory (Cardiovascular) systemDecompensation030212 general & internal medicineOriginal Research ArticleEjection fractionbusiness.industryProportional hazards modelInsulinHazard ratioType 2 Diabetes MellitusAcute heart failureHospital readmissionmedicine.diseaseHeart failureRC666-701Insulin therapyCardiology and Cardiovascular Medicinebusiness
researchProduct

From obesity to Alzheimer's disease through insulin resistance

2021

Alzheimer's disease is one of the most frequent forms of dementia. It is a progressive neurodegenerative disease, characterized by presence of amyloid plaques and neurofibrillary tangles in the brain. Obesity is regarded as abnormal fat accumulation with deleterious impact on human health. There is full scientific evidence that obesity and the metabolic comorbidities (e.g., insulin resistance, hyperglycaemia, and type 2 diabetes) are related to Alzheimer's disease and likely in the causative pathway. Numerous studies have identified several overlapping neurodegenerative mechanisms, including oxidative stress, mitochondrial dysfunction, and inflammation. In this review, we present how obesit…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismType 2 diabetesmedicine.disease_causeEndocrinologyInsulin resistanceDownregulation and upregulationAlzheimer DiseaseInternal medicineDiabetes mellitusInternal MedicinemedicineHumansDementiaObesityNeurodegenerationInflammationbusiness.industryNeurodegenerationBrainInsulin resistanceAlzheimer's diseasemedicine.diseaseEndocrinologyDiabetes Mellitus Type 2LipotoxicitybusinessOxidative stressJournal of Diabetes and its Complications
researchProduct

Frailty Is Associated with Oxidative Stress in Older Patients with Type 2 Diabetes

2021

Aging has increased the prevalence of frailty, and type 2 diabetes (T2D) has also increased in prevalence. Diabetes and oxidative stress (OS) have been shown to be related to frailty. However, the exact mechanism by which it occurs is not fully known. Our aim was to analyze body composition in community-dwelling older diabetic people treated in our center and to evaluate the possible relation between OS, frailty, and body composition. We included 100 adults older than 65 years with T2D. We found that 15% were frail and 57% were prefrail. The patients included in the nonrobust group showed increased levels of OS. Our study shows that the presence of T2D in the geriatric population is associa…

Malemedicine.medical_specialtyPopulationType 2 diabetesfrailtymedicine.disease_causeArticleCohort StudiesProtein CarbonylationOlder patientsGeriatric populationInternal medicineDiabetes mellitusMalondialdehydemedicinePrevalenceHumansoxidative stressTX341-641educationAgededucation.field_of_studybody compositionNutrition and Dieteticsdiabetesbusiness.industryNutrition. Foods and food supplyagingmedicine.diseaseDiabetes Mellitus Type 2Linear ModelsFemalebusinessOxidative stressFood ScienceNutrients
researchProduct

Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving…

2017

Aims The aim of the study was to investigate the effect of sequential treatment escalation with empagliflozin and linagliptin on laboratory markers of alpha- and beta cell function in patients with type 2 diabetes mellitus (T2DM) insufficiently controlled on metformin monotherapy. Methods Forty-four patients with T2DM received 25 mg empagliflozin for a duration of one month in an open-label fashion (treatment period (TP 1). Thereafter, patients were randomised to a double-blind add-on therapy with linagliptin 5 mg or placebo (TP 2) for one additional month. Alpha- and beta cell function were assessed with a standardised liquid meal test (LMT) and an intravenous (iv.) glucose challenge. Effi…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismLinagliptinType 2 diabetes030204 cardiovascular system & hematologyLinagliptinGlucagon03 medical and health sciences0302 clinical medicineEndocrinologyDouble-Blind MethodGlucosidesInternal medicineInsulin-Secreting CellsInternal MedicinemedicineEmpagliflozinHumansHypoglycemic AgentsInsulinBenzhydryl CompoundsProinsulinAgedbusiness.industryInsulinMiddle Agedmedicine.diseaseGlucagonPostprandial PeriodMetforminEndocrinologyPostprandialTreatment OutcomeDiabetes Mellitus Type 2Glucagon-Secreting CellsGlucose Clamp TechniqueFemalebusinessmedicine.drugProinsulinDiabetes, obesitymetabolism
researchProduct

Impact of diet-induced obesity on the mouse brain phosphoproteome

2018

Obesity is closely associated to several diseases such as type 2 diabetes, cardiovascular disease, hepatic steatosis, airway disease, neurodegeneration, biliary diseases and certain cancers. It is, therefore, of importance to assess the role of nutrition in disease prevention as well as its effect in the course of such pathologies. In the present study, we addressed the impact of the exposure to different obesogenic diets in the mice brains phosphoproteome. To analyze if the obesity could be able to modify the protein pattern expression of brain neurons, obesity was induced in two different groups of mice. One group of mice was fed with hyperglycemic diet (HGD) and the other one was fed wit…

Male0301 basic medicinemedicine.medical_specialtyPhosphoproteomicsEndocrinology Diabetes and MetabolismClinical BiochemistryHyperglycemic dietType 2 diabetesDiseaseBiologyDiet High-FatBiochemistry03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsProtein phosphorylationObesityPhosphorylationMolecular BiologyGSK3BNutritionNeuronal impairmentNutrition and DieteticsNeurodegenerationta1182BrainObesity; Nutrition; High-fat diet; Hyperglycemic diet; Neuronal impairment; PhosphoproteomicsPhosphoproteinsmedicine.diseaseObesityMice Inbred C57BLHigh-fat dietGene Ontology030104 developmental biologyEndocrinologyHyperglycemiaPhosphorylationCalcium ChannelsSteatosis030217 neurology & neurosurgeryThe Journal of Nutritional Biochemistry
researchProduct

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes

2018

Diabetes mellitus is a chronic disease prevalence of which is high and continually growing. Cardiovascular disease continues to be the leading cause of death in patients with T2DM. The prevention of cardiovascular complications and the cardiovascular safety of treatments should be a primary objective when selecting treatment. Among all the drugs available, the compounds known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appear to be not just innocuous in terms of CVD but indeed to be beneficial. GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic control, dyslipidaemia, weight, or arterial hypertension but also might …

Blood GlucoseEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetesDiseaseReview Article030204 cardiovascular system & hematologyBioinformaticslcsh:Diseases of the endocrine glands. Clinical endocrinologyIncretinsGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyDiabetes mellitusmedicineHumansHypoglycemic AgentsCause of deathSistema cardiovascularlcsh:RC648-665DiabetisLiraglutidebusiness.industrySemaglutidemedicine.diseaseClinical trialDiabetes Mellitus Type 2Cardiovascular DiseasesHeart failureMalaltiesbusinessmedicine.drugJournal of Diabetes Research
researchProduct

Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations fr…

2022

Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of the endogenous GLP-1 incretin hormone, improving glycaemic control in type 2 diabetes mellitus (T2DM) by increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. However, as cardiovascular (CV) morbidity and mortality is common in patients with T2DM, several trials with the use of GLP-1 receptor agonists (RAs) have been performed focusing on endpoints related to cardiovascular disease rather than metabolic control of T2DM. Following the positive cardiovascular effects of liraglutide, dulaglutide and semaglutide observed in these trials, major changes in T2DM management guidelines have …

Diabetes Mellitus Type 2Cardiovascular DiseasesGlucagon-Like Peptide 1HumansHypoglycemic AgentsAlgorithm Cardiovascular outcomes trials GLP-1 receptor agonists Treatment Type 2 diabetes mellitusLiraglutideCardiology and Cardiovascular MedicineAlgorithm ; Cardiovascular outcomes trials ; GLP-1 receptor agonists ; Treatment ; Type 2 diabetes mellitus.Glucagon-Like Peptide-1 ReceptorInternational Journal of Cardiology
researchProduct

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the…

2004

Aims Patients with diabetes are at excessive risk of mortality and cardiovascular morbidity. Previous studies suggest that aspirin may be less effective in diabetic patients. In this multi-centre, randomized, double blind trial picotamide, a dual inhibitor of thromboxane A2 synthase and receptor, was compared with aspirin for the prevention of mortality and major cardiovascular events in diabetics with peripheral arterial disease (PAD). Methods and results A total of 1209 adults aged 40–75 years with type 2 diabetes and PAD were randomized to receive picotamide (600 mg bid) or aspirin (320 mg od) for 24 months. The cumulative incidence of the 2 years overall mortality was significantly lowe…

AdultMalemedicine.medical_specialtyPhthalic AcidsType 2 diabetesDiabeteGastroenterologyThromboxane A2Double-Blind MethodRisk FactorsInternal medicineDiabetes mellitusPeripheral arterial diseasemedicineRisk of mortalityHumansPicotamideCumulative incidenceGeneral NursingAgedPeripheral Vascular DiseasesAspirinAspirinbiologybusiness.industryAntiplatelet therapyantiplatelet therapy; aspirin; diabetes; peripheral arterial disease; picotamide; thromboxane synthase inhibitorsMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryThromboxane synthase inhibitors Indexed keywordsRelative riskbiology.proteinFemaleThromboxane-A synthasePicotamideCardiology and Cardiovascular MedicinebusinessDiabetic AngiopathiesPlatelet Aggregation InhibitorsFollow-Up Studiesmedicine.drugEuropean Heart Journal
researchProduct